Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in ...

Inavolisib (Itovebi) plus fulvestrant and palbociclib (Ibrance) led to a statistically significant and clinically meaningful benefit in progression-free survival (PFS) vs fulvestrant and palbociclib ...

PIK3CA mutations are poor prognostic indicators in advanced breast cancer. Addition of the PI3K inhibitor inavolisib to palbociclib–fulvestrant might improve outcomes. New research findings are ...

The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA ...

As someone who has firsthand experience scaling a company sustainably, I have witnessed the profound impact that the organizational structure can have on long-term success. Through my experiences ...

It is approved in combination with Pfizer’s Ibrance (palbociclib) and fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. Itovebi is ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Phosphoinositides (PI) are key regulators of cellular organization in eukaryotes and genes that tune PI signaling are implicated in human disease mechanisms. Biochemical analyses and studies in ...